Literature DB >> 18602574

Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection.

Vincent R Bonagura, Robert Marchlewski, Amanda Cox, David W Rosenthal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602574     DOI: 10.1016/j.jaci.2008.04.044

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  66 in total

Review 1.  Considerations for dosing immunoglobulin in obese patients.

Authors:  J P Hodkinson
Journal:  Clin Exp Immunol       Date:  2017-04-17       Impact factor: 4.330

Review 2.  Polyvalent immunoglobulins: challenges and perspectives.

Authors:  Isabella Quinti; Serelina Coluzzi; Federica Pulvirenti; Alessandro Prezzo; Gabriella Girelli
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 3.  Clinical use of polyvalent immunoglobulins.

Authors:  Isabella Quinti; Anna Maria Pesce; Livia Bonanni; Carlotta Rubino; Federica Pulvirenti; Cinzia Milito
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

4.  Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD.

Authors:  Melvin Berger
Journal:  J Clin Immunol       Date:  2011-06-04       Impact factor: 8.317

5.  Use of subcutaneous immunoglobulin in primary immune deficiencies.

Authors:  Elif Karakoç Aydıner; Ayça Kıykım; Safa Barış; Ahmet Özen; Işıl Barlan
Journal:  Turk Pediatri Ars       Date:  2016-03-01

6.  Immunoglobulins: current understanding and future directions.

Authors:  S Jolles; S C Jordan; J S Orange; I N van Schaik
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

7.  Effective dosing strategies for therapeutic immunoglobulin: managing wear-off effects in antibody replacement to immunomodulation.

Authors:  S A Misbah
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

8.  Subclinical infection and dosing in primary immunodeficiencies.

Authors:  S Jolles
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

9.  Bioavailability of IgG administered by the subcutaneous route.

Authors:  Melvin Berger; Stephen Jolles; Jordan S Orange; John W Sleasman
Journal:  J Clin Immunol       Date:  2013-03-01       Impact factor: 8.317

Review 10.  Advances in basic and clinical immunology in 2008.

Authors:  Javier Chinen; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-02       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.